Clinical Trial Update: Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating orelabrutinib in combination with rituximab as first-line systemic therapy for marginal zone lymphoma; recruitment is ong…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Marginal Zone Lymphoma(MZL) | Phase 2 | Status: RECRUITING